Clin Mol Hepatol.
2024 Oct;30(4):689-691. 10.3350/cmh.2024.0348.
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”
- Affiliations
-
- 1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
- 2Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 3Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 4Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- KMID: 2560071
- DOI: http://doi.org/10.3350/cmh.2024.0348
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”
- Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
- Whole Blood Processing Using the Buffy-Coat Method
- Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
- The Genomic Landscape and Its Clinical Implications in Hepatocellular Carcinoma
